These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10426246)

  • 1. Calculating correct Down's syndrome risks.
    Cuckle H; Sehmi I
    Br J Obstet Gynaecol; 1999 Apr; 106(4):371-2. PubMed ID: 10426246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    BJOG; 2004 Jun; 111(6):521-31. PubMed ID: 15198778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome.
    Thilaganathan B; Slack A; Wathen NC
    Ultrasound Obstet Gynecol; 1997 Oct; 10(4):261-4. PubMed ID: 9383877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The distribution of nuchal translucency at 10-13 weeks of pregnancy.
    Schuchter K; Wald N; Hackshaw AK; Hafner E; Liebhart E
    Prenat Diagn; 1998 Mar; 18(3):281-6. PubMed ID: 9556045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome.
    Kadir RA; Economides DL
    Ultrasound Obstet Gynecol; 1997 Apr; 9(4):244-7. PubMed ID: 9168574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency.
    Orlandi F; Damiani G; Hallahan TW; Krantz DA; Macri JN
    Ultrasound Obstet Gynecol; 1997 Dec; 10(6):381-6. PubMed ID: 9476320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First trimester nuchal translucency: effective routine screening for Down's syndrome.
    Thilaganathan B; Sairam S; Michailidis G; Wathen NC
    Br J Radiol; 1999 Oct; 72(862):946-8. PubMed ID: 10673944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
    Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H
    Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of routine screening for Down's syndrome on the significance of isolated fetal hydronephrosis.
    Thompson MO; Thilaganathan B
    Br J Obstet Gynaecol; 1998 Aug; 105(8):860-4. PubMed ID: 9746378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down's syndrome screening with nuchal translucency at 12(+0)-14(+0) weeks and maternal serum markers at 14(+1)-17(+0) weeks: a prospective study.
    Rozenberg P; Malagrida L; Cuckle H; Durand-Zaleski I; Nisand I; Audibert F; Benattar C; Tribalat S; Cartron M; Lemarié P; Stoessel J; Capolagui P; Jansé-Marec J; Barbier D; Allouch C; Perdu M; Roberto A; Lahna Z; Giudicelli Y; Ville Y
    Hum Reprod; 2002 Apr; 17(4):1093-8. PubMed ID: 11925411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prenatal screening for Down's syndrome with use of maternal serum markers.
    Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
    N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of ethnic origin on nuchal translucency screening for Down's syndrome.
    Thilaganathan B; Khare M; Williams B; Wathen NC
    Ultrasound Obstet Gynecol; 1998 Aug; 12(2):112-4. PubMed ID: 9744055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for Down's syndrome in the first trimester: combined risk calculation, methodology, and validation of a web-based system.
    Kublickas M; Crossley J; Aitken D
    Acta Obstet Gynecol Scand; 2009; 88(6):635-8, 7p following 638. PubMed ID: 19330568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [First trimester ultrasound screening for nuchal translucency as marker of Down's syndrome].
    Herman A; Maymon R; Dreazen E; Bukovsky I; Weinraub Z
    Harefuah; 1997 Jan; 132(2):94-100. PubMed ID: 9119309
    [No Abstract]   [Full Text] [Related]  

  • 17. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study.
    Audibert F; Dommergues M; Benattar C; Taieb J; Thalabard JC; Frydman R
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):26-31. PubMed ID: 11489221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome.
    Wald NJ; Hackshaw AK
    Prenat Diagn; 1997 Sep; 17(9):821-9. PubMed ID: 9316126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.